FRANKFURT: Europe’s STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk ...

Health insurers such as UnitedHealth Group and Cigna also recovered some of their recent losses following public controversy about industry practices in the wake of the assassination of UnitedHealth ...

EUROPE’S Stoxx 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The STOXX 600 index started the week with a slight decline during a holiday-shortened trading session. Novo Nordisk shares spiked, bolstering the healthcare sector and limiting overall losses. Travel ...

The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.

Europe's STOXX 600 ended the day slightly up, driven by a surge in Novo Nordisk shares that helped the healthcare sector. Low trading volumes characterized the day due to holiday anticipation, while ...

Novo Nordisk's CagriSema fell short of weight loss goals, causing 17% stock drop. Drug shows similar results to Eli Lilly's ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.